Terms: = Prostate cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
13 results:
1. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a her-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract] [Full Text] [Related]
2. A pilot study in prostate cancer patients treated with the AE37 Ii-key-her-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract] [Full Text] [Related]
3. PTEN Loss Is Associated with Worse outcome in her2-Amplified Breast cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract] [Full Text] [Related]
4. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
[TBL] [Abstract] [Full Text] [Related]
5. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.
Wang T; Liu Z; Guo S; Wu L; Li M; Yang J; Chen R; Xu H; Cai S; Chen H; Li W; Wang L; Hu Z; Zhuang Q; Xu S; Wang L; Liu J; Ye Z; Ji JY; Wang C; Chen K
Oncotarget; 2014 Jun; 5(11):3611-21. PubMed ID: 25003983
[TBL] [Abstract] [Full Text] [Related]
6. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
[TBL] [Abstract] [Full Text] [Related]
7. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract] [Full Text] [Related]
8. Prophylactic vaccines for prevention of prostate cancer.
Naz RK; Shiley B
Front Biosci (Schol Ed); 2012 Jan; 4(3):932-40. PubMed ID: 22202100
[TBL] [Abstract] [Full Text] [Related]
9. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Sridhar SS; Hotte SJ; Chin JL; Hudes GR; Gregg R; Trachtenberg J; Wang L; Tran-Thanh D; Pham NA; Tsao MS; Hedley D; Dancey JE; Moore MJ
Am J Clin Oncol; 2010 Dec; 33(6):609-13. PubMed ID: 20042973
[TBL] [Abstract] [Full Text] [Related]
11. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.
Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK
Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880
[TBL] [Abstract] [Full Text] [Related]
13. Serum her2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
[TBL] [Abstract] [Full Text] [Related]
